Previous 10 | Next 10 |
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023. John V. Oyler, BeiGene's Co-Founder, Chairman and CEO, along with the Compan...
BeiGene, Ltd. (NASDAQ: BGNE) is one of today's top gainers. The company's shares are currently up 5.7% on the day to $191.16. BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internat...
2023-06-21 01:45:00 ET Summary A unit of AbbVie has sued BeiGene for alleged patent infringement involving one of the Chinese company’s core products, Brukinsa. The lawsuit comes amid rapidly growing sales for Brukinsa, which is used to treat blood cancer, even as sales for...
2023-06-20 06:39:41 ET Summary Today, we revisit an oncology focused developmental concern called Zymeworks, Inc. The company continues to advance its lead drug candidate, has a huge potential partnership with Jazz Pharmaceuticals and a large cash hoard. The stock has spent mo...
The law firm of Kirby McInerney LLP is investigating potential claims against BeiGene Ltd. (“BeiGene” or the “Company”) (NASDAQ: BGNE ). The investigation concerns whether BeiGene and/or certain of its officers have violated the federal securities laws and/or e...
2023-06-15 13:51:45 ET Summary BeiGene, a global biotech company focused on oncology treatments, has experienced significant revenue growth in Q1 2023, with product revenue contributing to the increase. AbbVie, a pharmaceutical giant, has filed a patent infringement lawsuit agains...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is aware that Pharmacyclics LLC has filed a complaint against BeiGene, Ltd. and BeiGene USA, Inc., alleging that BeiGene’s BRUKINSA® infringes a Pharmacyclics patent issued on June 13, 2023. BeiGene ...
2023-06-15 08:24:35 ET Mersana Therapeutics ( MRSN ) -67% on FDA partial hold on trials for lead asset. Bone Biologics Corporation ( BBLG ) -53% on offering prices of $5M . Gambling.com Group Limited ( GAMB ) -15% launches secondary offering of 4....
Oral presentation for the ROSEWOOD trial of BRUKINSA in relapsed or refractory follicular lymphoma Additional presentations expand existing evidence base for BRUKINSA across B-cell malignancies BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology compan...
2023-06-14 06:28:00 ET Summary We’ve seen signs of improvement that are positive for the Chinese internet services sector, but that space also continues to be a place of extreme competitive aggression. As a result of the creation of economic zones, increased availability of...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...